In addition to the vertical signaling cascades involved in resistance, parallel pathways can bypass KRAS G12C inhibition through a variety of mechanisms, including tumour microenvironment alterations, alterations in cell cycle regulators, and phenotypic transformation. The gene discussed is KRAS; the disease is neoplasm.